SEC Filing Report: Cellectis S.A. – Form 20-F/A (Amendment No. 1)
Executive Summary
This report analyzes Cellectis S.A.’s Form 20-F/A (Amendment No. 1) filed on March 14, 2025. This amendment solely addresses administrative errors in the original filing related to the auditor consents (Exhibits 15.1 and 15.2). The original filing date remains relevant for all other information. No new financial data or operational updates are included. Therefore, this report focuses on the implications of the auditor consent corrections and refers back to the original 20-F filing for a comprehensive analysis of Cellectis’ financial health and future prospects. The correction of these errors is a positive sign of attention to detail in regulatory filings.
Company Overview
Cellectis S.A. is a gene editing company focused on developing allogeneic CAR-T cell therapies for cancer. The company utilizes its proprietary TALEN® technology for gene editing. AstraZeneca has a significant investment in Cellectis.
Detailed Analysis
Filing Type and Purpose
This is an amendment (Amendment No. 1) to the original Form 20-F, an annual report for foreign private issuers. The sole purpose of this amendment is to correct administrative errors in the auditor consents provided as exhibits to the original filing.
Amendment Details
* **Exhibit 15.1 (Consent of KPMG SA):** The conformed signature of KPMG SA was inadvertently omitted in the original filing.
* **Exhibit 15.2 (Consent of Ernst & Young et Autres):** The incorrect date of the consent was inadvertently included in the original filing.
The amendment includes the corrected exhibits and new certifications from the CEO and CFO related to the accuracy of the amended filing.
Implications of the Amendment
The correction of these errors is important for maintaining the integrity of the SEC filing. While the errors were administrative in nature, their correction demonstrates Cellectis’ commitment to accurate and compliant reporting. The auditor consents are crucial as they provide assurance on the reliability of the financial statements.
Reference to Original 20-F Filing
Since this amendment does not contain any new financial data or operational updates, a comprehensive analysis of Cellectis’ financial performance, risk factors, and management discussion and analysis (MD&A) requires a review of the original Form 20-F filed on March 14, 2025. Key areas to focus on in the original filing include:
* **Financial Statements:** Analyze the income statement, balance sheet, and cash flow statement to assess Cellectis’ revenue, expenses, assets, liabilities, and cash flow generation. Key ratios to examine include cash burn rate, R&D expenses as a percentage of revenue, and liquidity ratios.
* **Management’s Discussion and Analysis (MD&A):** Evaluate management’s commentary on the company’s performance, key trends, and future outlook. Pay attention to discussions of clinical trial progress, partnerships, and financial strategy.
* **Risk Factors:** Carefully review the risk factors section to understand the challenges and uncertainties facing Cellectis. Key risks may include clinical trial failures, regulatory hurdles, competition, and financial risks.
* **Agreements:** Review the agreements with AstraZeneca and Servier.
Conclusion and Actionable Insights
This amendment (Form 20-F/A) is a procedural update to correct administrative errors in the auditor consents. It does not alter the fundamental financial or operational picture of Cellectis. Investors should refer to the original Form 20-F filing for a comprehensive understanding of the company’s performance, risks, and opportunities. The correction of these errors is a positive sign of attention to detail in regulatory filings.